

### REMARKS

Claims 1-32, 36-38, and 46-54 have been canceled. Claims 33, 35, 39 and 45 have been amended. New claims 55-71 have been added. After entry of this amendment, claims 33-35, 39-45 and 55-71 are pending.

The amendments to the claims are fully supported by the specification. The amendments to claims 33 and 39 and new claim 62 are supported by, *e.g.*, page 26, lines 3-4. The amendments to claims 35 and 45 are supported by, *e.g.* the existing claims and the specification, page 24, line 17. New claims 55-71 are supported by, *e.g.*, page 23, lines 7-12; pages 1-4 and page 24, lines 12-15 of the specification. Therefore, it is believed that no new matter has been added.

#### *The Restriction Requirement Under 35 U.S.C. § 121*

The Examiner has required an election under 35 U.S.C. § 121 to one of the following groups of claims:

- |            |                                                                                                                                                                                |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Group I.   | Claims 1-16 and 30-32, drawn to a method of treating healed wounds, classified in class 424, subclass 443;                                                                     |
| Group II.  | Claims 17-29, drawn to a method of treating immunological skin disorders, classified in class 424, subclass 401;                                                               |
| Group III. | Claims 33-35 and 39-45, drawn to a method of administering an analgesic and a method of providing an internal physiological effect, classified in class 424, subclass 449; and |
| Group IV.  | Claims 36-38 and 46-54, drawn to a method of treating cancer and a composition comprising a topically effective anesthetic, classified in class 424, subclass 78.03.           |

The Examiner further indicates that if Group III is elected, an Election of Species to elect a single disclosed species under the elected group is also required. The species under Group III are:

- (a) Vasodilator;
- (b) Suppressor of drug-addictive cravings;
- (c) Nicotine;
- (d) Bronchial dilator; and
- (e) Antihistamine.

Applicant hereby elects the invention of **Group III**, the subject matter of **claims 33-35 and 39-45**. Applicant hereby elects species (e), *i.e.*, antihistamine, under Group III. It is believed that upon allowance of a generic claim(s), applicant is entitled to consideration and allowance of the non-elected species.


**CONCLUSION**

In view of the above amendments and remarks, applicants respectfully submit that the claims are now in condition for allowance, early notice of which is earnestly sought.

No fee, other than the fee for extension of time, is believed to be due for this submission. Should any additional fees be required, please charge such fees to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: July 18, 2003

  
Geraldine F. Baldwin 31,232  
(Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711

(212) 790-9090

Attorneys for Applicant